Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 592.10M | 693.20M | 653.00M | 651.60M | 585.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 592.10M | 693.20M | 653.00M | 651.60M | 585.40M |
| Cost of Revenue | 282.70M | 348.40M | 310.20M | 306.20M | 279.40M |
| Gross Profit | 309.40M | 344.80M | 342.80M | 345.40M | 306.00M |
| SG&A Expenses | 212.40M | 217.30M | 204.20M | 205.00M | 208.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 558.00M | 631.70M | 585.00M | 572.00M | 561.70M |
| Operating Income | 34.10M | 61.50M | 68.00M | 79.60M | 23.70M |
| Income Before Tax | -689.80M | 929.20M | -431.10M | 414.00M | 83.40M |
| Income Tax Expenses | -162.70M | 209.20M | -89.20M | 96.20M | 19.40M |
| Earnings from Continuing Operations | -527.10M | 720.00M | -341.90M | 317.80M | 64.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -527.10M | 720.00M | -341.90M | 317.80M | 64.00M |
| EBIT | 34.10M | 61.50M | 68.00M | 79.60M | 23.70M |
| EBITDA | 75.00M | 104.00M | 112.20M | 120.20M | 61.80M |
| EPS Basic | -19.55 | 26.69 | -12.70 | 11.67 | 2.29 |
| Normalized Basic EPS | 1.06 | 1.90 | 1.66 | 1.86 | 1.14 |
| EPS Diluted | -19.55 | 26.65 | -12.70 | 11.67 | 2.29 |
| Normalized Diluted EPS | 1.06 | 1.90 | 1.66 | 1.86 | 1.14 |
| Average Basic Shares Outstanding | 26.96M | 26.98M | 26.92M | 27.23M | 27.94M |
| Average Diluted Shares Outstanding | 26.96M | 27.01M | 26.92M | 27.23M | 27.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |